Read the findings & sources
Human study discussedSURMOUNT-1 studied 2,539 adults with overweight or obesity without diabetes over 72 weeks. Mean weight reductions were 15.0%, 19.5% and 20.9% across its three tirzepatide treatment groups, versus 3.1% with placebo. Gastrointestinal adverse events were common, particularly during escalation. These results describe the trial's specific treatment groups and analysis; they are not interchangeable with results for mixed preparations or other formulations.